Patheon, a global provider of pharmaceutical development and manufacturing services, announced that Patrick Glaser was appointed senior vice president of the company’s small molecule active pharmaceutical ingredient (API) business. He will be responsible for leading the transformation and expansion of the company’s API service offering in Europe and North America and will report to Lukas Utiger, president of Patheon’s drug substance services division.
Glaser joins Patheon from Teva Pharmaceutical Industries where he served as vice president of sales and marketing, API, North America and had business responsibility for more than 300 APIs. He previously held senior management, strategic marketing and business development positions at Novasep Groupe where he was president and CEO. Glaser had global responsibility for three business units: synthesis, biopharma and industrial biotech, and also managed the divestiture of non-core Novasep businesses.
“Patrick brings more than 20 years of leadership experience in the pharmaceutical industry,” said Utiger. ”We will benefit from his depth of knowledge of the industry and expertise in strategic business development as we work to continue expanding our API business.”
Glaser earned a bachelor of arts in economics from Fairleigh Dickinson University in Madison, NJ. He previously was a member of the board of directors of the Drug Chemical and Associated Technologies Association (DCAT).